Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (4): 523-530    DOI: 10.31083/j.ejgo.2020.04.8051
Original Research Previous articles | Next articles
The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer
Silvia Ortega1, José Angel Mínguez2, José Manuel Aramendía3, Marta Santisteban3, Fernando Martinez-Regueira4, Pablo Martí-Cruchaga4, Juan Luis Alcázar2, *(), Matías Jurado2
1Department of Obstetrics and Gynecology, Hospital Miguel Servet, Paseo Isabel la Católica, 1-3, 50009, Zaragoza, Spain
2Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain
3Department of Medical Oncology, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008 Pamplona, Spain
4Department of Surgery, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008 Pamplona, Spain
Download:  PDF(203KB)  ( 270 ) Full text   ( 23 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: Analyze the effect on survival of secondary cytoreduction surgery (SCS) in treatment of first recurrence platinum-sensitive epithelial ovarian cancer (REOC). Methods: Retrospective analysis of patients with first REOC who had platinum time-free interval (TFIp) > 6 months and were treated either with SCS followed by chemotherapy or chemotherapy only (CT). Clinical data such as patient's performance status and number of sites with metastases were specifically assessed. The primary endpoint was overall survival (OS). Results: Seventy-one patients were treated either by SCS (n = 37) or CT (n = 34). Complete resection after SCS was achieved in 89% of patients. After a median follow-up of 51.2 months, median OS, and progression-free survival (PFS) were 68.2 and 21.6 months, respectively, for the whole series of the SCS patients had better survival and disease progression survival than the CT only patients (HR: 0.33, 95%CI: 0.17-0.6; p = 0.001) and (HR: 0.28, 95%CI: 0.15-0.5; p = 0.001), respectively. TFIp < 12 months and multiple metastases were most important prognostic factors for risk of death (HR: 7.7 and 6.2, respectively) and recurrence (HR: 5.8 and 3.8, respectively). Probability to undergo successful SCS is related to oligometastatic disease and no residual disease after first surgery (OR: 30.0 and 5.9, respectively). Conclusions: In women with REOC oligometastatic disease and no residual disease at first surgery are associated with successful SCS. In these patients oligometastatic disease and long platinum TFI are associated with improved probability of survival.
Key words:  Ovarian cancer      Recurrence      Secondary cytoreductive surgery      Survival      Morbidity     
Submitted:  22 July 2020      Accepted:  06 August 2020      Published:  15 August 2020     
*Corresponding Author(s):  JUAN LUIS ALCÁZAR     E-mail:  jlalcazar@unav.es

Cite this article: 

Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.04.8051     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I4/523

[1] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[2] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[3] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[4] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[5] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[6] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
[7] C.J. Heesterbeek, A.M. Thijs, R.H.M. Hermans, D. Boll, G.-J. Creemers. Bevacizumab in combination with metronomic oral cyclophosphamide: an effective and well-tolerated treatment for patients with recurrent ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 364-367.
[8] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[9] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[10] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[11] Lindsey Buckingham, Lori Cory, Colleen Brensinger, Xiaochen Zhang, Robert A. Burger, Fiona Simpkins, Emily M. Ko. Epidemiologic profile of benign versus oncologic gynecology populations: similar procedures, different patients[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 396-401.
[12] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[13] Xiaofeng Xu, Xuan Zhou, Yijin Wang, Tao Liu, Jian Fu, Qian Yang, Jun Wu, Huaijun Zhou. Survival-associated transcriptome analysis in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 455-461.
[14] M.E. Căpîlna, B. Szabo, J. Becsi, M. Morariu, M. Gheorghe, S.L. Kiss, B. Moldovan. Surgical complications and survival after pelvic exenteration: our experience following 60 procedures[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 171-175.
[15] L.D. Gutierrez-Castañeda, J.F. Polo, C. Carmona, D. Sanabria, D.M. Caballero, A. Jutinico, R. Parra-Medina. Expression of heat shock protein Hsp 27 in ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 221-226.
No Suggested Reading articles found!